These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer. Khurana N; Dodhiawala PB; Bulle A; Lim KH Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32961746 [TBL] [Abstract][Full Text] [Related]
3. Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches. Truong LH; Pauklin S Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638513 [TBL] [Abstract][Full Text] [Related]
4. Highlights on the Role of Hafezi S; Saber-Ayad M; Abdel-Rahman WM Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638560 [TBL] [Abstract][Full Text] [Related]
5. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations. Dodhiawala PB; Khurana N; Zhang D; Cheng Y; Li L; Wei Q; Seehra K; Jiang H; Grierson PM; Wang-Gillam A; Lim KH J Clin Invest; 2020 Sep; 130(9):4771-4790. PubMed ID: 32573499 [TBL] [Abstract][Full Text] [Related]
6. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer. Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173 [TBL] [Abstract][Full Text] [Related]
7. Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies. Linehan A; O'Reilly M; McDermott R; O'Kane GM Front Med (Lausanne); 2024; 11():1369136. PubMed ID: 38576709 [TBL] [Abstract][Full Text] [Related]
8. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123 [TBL] [Abstract][Full Text] [Related]
9. Advances in Pancreatic Ductal Adenocarcinoma Treatment. Anderson EM; Thomassian S; Gong J; Hendifar A; Osipov A Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771675 [TBL] [Abstract][Full Text] [Related]
10. Apoptosis in the Pancreatic Cancer Tumor Microenvironment-The Double-Edged Sword of Cancer-Associated Fibroblasts. Pfeifer E; Burchell JM; Dazzi F; Sarker D; Beatson R Cells; 2021 Jul; 10(7):. PubMed ID: 34359823 [TBL] [Abstract][Full Text] [Related]
11. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203 [TBL] [Abstract][Full Text] [Related]
12. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115 [TBL] [Abstract][Full Text] [Related]
13. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS. Xie F; Li C; Zhang X; Peng W; Wen T Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891 [TBL] [Abstract][Full Text] [Related]
14. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. Polani F; Grierson PM; Lim KH World J Gastroenterol; 2021 May; 27(18):2105-2121. PubMed ID: 34025067 [TBL] [Abstract][Full Text] [Related]
15. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer. Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808 [TBL] [Abstract][Full Text] [Related]
16. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025 [TBL] [Abstract][Full Text] [Related]
17. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. Rozengurt E; Eibl G World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295 [TBL] [Abstract][Full Text] [Related]
18. Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment. Yamamoto K; Iwadate D; Kato H; Nakai Y; Tateishi K; Fujishiro M Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139512 [TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity for Kras Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996 [TBL] [Abstract][Full Text] [Related]
20. Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. Smigiel JM; Parameswaran N; Jackson MW Cancers (Basel); 2018 Jan; 10(1):. PubMed ID: 29320425 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]